

**Online Supplementary Material**

Croswell JM, Kramer BS, Kreimer AR, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. *Ann Fam Med.* 2009;7(3):212-222..

<http://www.annfammed.org/cgi/content/full/7/3/212/DC1>

<b>Supplemental Table 1. Estimators and 95% Confidence Intervals of the Cumulative Risk of Receiving at Least 1 False-Positive Result in 14 Tests</b>		
<b>Test Number</b>	<b>Women</b>	<b>Men</b>
	<b>False Positive % (95% CI)</b>	<b>False Positive % (95% CI)</b>
1	2.1 (2.0-2.3)	5.7 (5.4-5.9)
2	10.9 (10.5-11.2)	14.9 (14.5-15.2)
3	15.3 (14.9-15.7)	20.3 (19.9-20.8)
4	26.2 (25.7-26.8)	36.7 (36.2-37.3)
5	28.1 (27.5-28.7)	38.7 (38.1-39.3)
6	31.6 (31.0-32.3)	42.0 (41.4-42.5)
7	33.7 (33.0-34.3)	44.4 (43.9-45.0)
8	35.4 (34.5-36.3)	46.4 (45.7-47.0)
9	38.3 (37.3-39.3)	48.9 (48.2-49.5)
10	40.0 (39.3-40.7)	51.1 (50.5-51.7)
11	41.7 (41.0-42.5)	52.9 (52.3-53.6)
12	43.9 (43.2-44.7)	55.1 (54.5-55.8)
13	46.0 (45.2-46.8)	57.3 (56.6-58.0)
14	48.8 (48.1-49.4)	60.4 (59.8-61.0)

CI = confidence interval.

## Online Supplementary Data

<http://www.annfammed.org/cgi/content/full/7/3/212/DC1>

**Supplemental Table 2. Estimators and 95% Confidence Intervals of the Cumulative Risk of Receiving at Least 1 False-Positive Result, by Screening Modality**

<b>Men</b>				
<b>Test</b>	<b>CXR</b> % (95% CI)	<b>FSG</b> % (95% CI)	<b>PSA</b> % (95% CI)	<b>DRE</b> % (95% CI)
1	9.2 (8.9-9.5)	24.3 (23.8-24.8)	5.4 (5.2-5.7)	6.4 (6.2-6.7)
2	14.0 (13.6-14.5)	41.8 (40.9-42.7)	7.9 (7.5-8.3)	10.5 (10.0-10.9)
3	18.1 (17.5-18.7)		10.4 (9.8-11.0)	14.2 (13.6-14.8)
4	22.3 (21.4-23.2)		12.9 (12.1-3.8)	17.6 (16.8-18.5)
<b>Women</b>				
<b>Test</b>	<b>CXR</b> % (95% CI)	<b>FSG</b> % (95% CI)	<b>CA-125</b> % (95% CI)	<b>TVU</b> % (95% CI)
1	8.0 (7.8-8.3)	16.1 (15.6-16.5)	1.3 (1.2-1.5)	4.5 (4.3-4.7)
2	13.0 (12.5-13.5)	29.2 (28.3-30.0)	2.3 (1.8-2.9)	7.3 (6.8-7.8)
3	17.2 (16.5-17.8)		3.3 (2.5-4.1)	9.7 (9.0-10.4)
4	21.5 (20.6-22.4)		4.2 (3.1-5.2)	12.1 (11.1-13.1)

CA = cancer antigen 125; CI = confidence interval; CXR = chest radiograph; DRE = digital rectal examination; FSG = flexible sigmoidoscopy; PSA = prostate-specific antigen; TVU = transvaginal ultrasonography.

**Supplemental Table 3. Estimators and 95% Confidence Intervals of the Cumulative Risk of Receiving at Least 1 Invasive Diagnostic Procedure as a Result of a False-Positive Screening Test**

Test Number	Women	Men
	False Positive % (95% CI)	False Positive % (95% CI)
1	0.2 (0.1-0.2)	1.6 (1.5-1.7)
2	1.7 (1.6-1.9)	2.5 (2.3-2.6)
3	3.6 (3.3-3.9)	3.7 (3.4-3.9)
4	12.3 (11.8-12.8)	17.2 (16.7-17.6)
5	12.8 (12.1-13.5)	18.2 (17.6-18.7)
6	13.4 (12.7-14.1)	18.7 (18.1-19.2)
7	14.5 (13.7-15.2)	19.7 (19.1-20.3)
8	15.2 (14.0-16.4)	20.7 (20.0-21.4)
9	16.0 (14.6-17.4)	21.3 (20.5-22.1)
10	17.0 (16.2-17.8)	22.3 (21.6-23.0)
11	17.9 (17.0-18.8)	23.6 (22.8-24.4)
12	18.9 (18.0-19.8)	24.4 (23.6-25.2)
13	20.1 (19.2-21.0)	25.8 (24.8-26.7)
14	22.1 (21.4-22.7)	28.5 (27.8-29.3)

CI = confidence interval.

## Online Supplementary Data

<http://www.annfammed.org/cgi/content/full/7/3/212/DC1>

**Supplemental Table 4. Estimators and 95% Confidence Intervals of the Cumulative Risk of Receiving at Least 1 Invasive Diagnostic Procedure as a Result of a False-Positive Screening Test, by Screening Modality**

<b>Men</b>				
<b>Test</b>	<b>CXR % (95% CI)</b>	<b>FSG % (95% CI)</b>	<b>PSA % (95% CI)</b>	<b>DRE % (95% CI)</b>
1	0.1 (0.1 to 0.2)	16.7 (16.3 to 29.2)	1.7 (1.5 to 1.8)	1.2 (1.1 to 1.4)
2	0.2 (-0.2 to 0.7)	30.1 (29.2 to 31.1)	3.0 (2.5 to 3.4)	2.3 (1.9 to 2.8)
3	0.3 (-0.4 to 1.0)		4.2 (3.5 to 4.9)	3.3 (2.7 to 4.0)
4	0.4 (-0.7 to 1.4)		5.5 (4.6 to 6.5)	4.4 (3.5 to 5.4)
<b>Women</b>				
<b>Test</b>	<b>CXR % (95% CI)</b>	<b>FSG % (95% CI)</b>	<b>CA-125 % (95% CI)</b>	<b>TVU % (95% CI)</b>
1	0.2 (0.1 to 0.2)	11.8 (11.5 to 12.2)	0.2 (0.1 to 0.2)	1.8 (1.7 to 2.0)
2	0.3 (-0.2 to 0.8)	22.1 (21.2 to 23.0)	0.4 (-0.2 to 1.0)	3.6 (3.1 to 4.2)
3	0.4 (-0.4 to 1.7)		0.7 (-0.1 to 1.5)	5.2 (4.4 to 6.0)
4	0.5 (-0.5 to 1.5)		1.0 (-0.1 to 2.1)	6.7 (5.6 to 7.7)

CA = cancer antigen 125; CI = confidence interval; CXR = chest radiograph; DRE = digital rectal examination; FSG = flexible sigmoidoscopy; PSA = prostate-specific antigen; TVU = transvaginal ultrasonography.